Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
14 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
LDI INTERNATIONAL from Antwerpen, company number BE0472156309, closed financial year 2025 with a result of € 2.8 million after tax. For that financial year LDI INTERNATIONAL recorded a gross margin of € 3.1 million and equity of € 3.3 million. Compared with financial year 2024, the result moved from € -521,861 to € 2.8 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 29, 2026.
€ 3.3 million
▲ € 2.8 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2.8 million
▲ still € 521,861 loss in 2024
Profit after tax over the fiscal year.
€ 566,065
▲ € 440,791 vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 3.2 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3.1 million
▼ 15% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 147,922
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 93,747 | € 971,161 | € -75,078 | € 3,072,662 | ▲ € 3.1 million |
| Profit after taxes | € -90,165 | € 587,593 | € -521,861 | € 2,818,402 | ▲ € 3.3 million |
| Equity | € 277,987 | € 865,580 | € 436,233 | € 3,254,634 | ▲ € 2.8 million |
| Total debts | € 1,876,845 | € 2,752,316 | € 4,658,107 | € 3,454,890 | ▼ 26% |
| Cash | € 31,829 | € 836,921 | € 125,274 | € 566,065 | ▲ € 440,791 |
| Retained profit | € 212,987 | € 800,580 | € 357,518 | € 3,175,919 | ▲ € 2.8 million |
| Dividend | € 339,950 | € 0 | € 0 | € 0 | |
| Bank debt | € 1,343,017 | € 0 | € 994,577 | € 0 | ▼ 100% |
| Balance sheet total | € 2,154,832 | € 3,617,896 | € 5,094,340 | € 6,709,524 | ▲ 32% |
Key figures of LDI INTERNATIONAL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to LDI INTERNATIONAL?
What happened at LDI INTERNATIONAL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Mark Jacobs stepped down as director. NBB
- M.D.R. BV stepped down as director. NBB
- Antoine Vandamme stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 2.8 million. Source: NBB ↗
- Mark Jacobs became a director. NBB
- M.D.R. BV became a director. NBB
- Antoine Vandamme became a director. NBB
- New establishment in Antwerpen. KBO
In short
From € 90,165 loss in 2022 to € 2.8 million profit in 2025.
Paid € 333,832 in corporate taxes since 2022.
Best year ever: 2025, with € 2.8 million profit.
Paid out € 339,950 in dividends to the owners in total.
A new publication or filing at LDI INTERNATIONAL? We notify you, reason included.
Follow LDI INTERNATIONALDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Manuchar comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
LDI INTERNATIONALThe shares are held by Manuchar (100%).
Directors
According to the 2025 annual accounts
Mark Jacobs
Director
since 2026 · until 2032
Director · represented by Matthias De Raeymaeker
Also active at: Manuchar, UNIT ONE, ACTIVIOR, MANUCHAR GROUP, Manuchar Europe, Manuchar Wood, Manuchar Pulp & Paper, Manuchar International Trade Services +1 more
since 2025 · until 2030
Antoine Vandamme
Director
since 2025 · until 2030
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rietschoorvelden 20
2170 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 14 companies are registered at this address.
All companies at this address →Manuchar same network
€ 570.5 million revenue · 2025
UNIT ONE same network
€ 90,316 gross margin · 2025
MANUCHAR GROUP same network
LSF XI Magpie Finco
€ 9,875 gross margin · 2025
Flamengo investments
€ -5,481 gross margin · 2024
+9 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0472.156.309
- VAT number
- BE 0472.156.309
- Registered office
- Rietschoorvelden 20, 2170 Antwerpen
- Names & denominations
- LDI INTERNATIONAL
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 21 June 2000
- Peppol
- Active · Active since 30 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten